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Abstract
Background: Head and neck squamous cell carcinoma (HNSCC) is responsible for over 20,000 deaths every year in
United States. Most of the deaths are due, in large part, to its propensity to metastasize. We have examined the
effect of bioactive component grape seed proanthocyanidins (GSPs) on human cutaneous HNSCC cell invasion and
the molecular mechanisms underlying these effects using SCC13 cell line as an in vitro model.
Methods: The therapeutic effects of GSPs on cancer cell invasion were studied using Boyden chamber and wound
healing assays. The effects of GSPs on the levels of various proteins related with cancer cell invasion were
determined using western blot analysis.
Results: Using in vitro cell invasion assays, we observed that treatment of SCC13 cells with GSPs resulted in a
concentration-dependent inhibition of cell invasion of these cells, which was associated with a reduction in the
levels of epidermal growth factor receptor (EGFR). Treatment of cells with gefitinib and erlotinib, inhibitors of EGFR,
or transient transfection of SCC13 cells with EGFR small interfering RNA, also inhibited invasion of these cells. The
inhibition of cell invasion by GSPs was associated with the inhibition of the phosphorylation of ERK1/2, a member
of mitogen-activated protein kinase family. Treatment of cells with UO126, an inhibitor of MEK, also inhibited the
invasion potential of SCC13 cells. Additionally, inhibition of human cutaneous HNSCC cell invasion by GSPs was
associated with reversal of epithelial-to-mesenchymal transition (EMT) process, which resulted in an increase in the
levels of epithelial biomarker (E-cadherin) while loss of mesenchymal biomarkers (vimentin, fibronectin and N-
cadherin) in cells. Similar effect on EMT biomarkers was also observed when cells were treated with erlotinib.
Conclusion: The results obtained from this study indicate that grape seed proanthocyanidins have the ability to
inhibit the invasion of human cutaneous HNSCC cells by targeting the EGFR expression and reversing the process
of epithelial-to-mesenchymal transition. These data suggest that GSPs can be developed as a complementary and
alternative medicine for the prevention of invasion/metastasis of HNSCC cells.
Background
Head and neck squamous cell carcinoma (HNSCC)
affects more than 40,000 people in the United States
annually and is responsible for over 20,000 deaths every
year [1,2]. HNSCC often generates from critical organs
including the oral cavity, larynx, pharynx, and tongue
that play indispensable roles in increased mortality rate
[1]. Head and neck cutaneous SCC is also very common.
Advances in surgical and medical therapies for HNSCC
have only modestly improved the mortality rate, which
has remained at 50% for the last three decades [3-6]. It
has been demonstrated that epidermal growth factor
receptor (EGFR), one of the ErbB family of receptors,
which is overexpressed in over 90% of HNSCC tumors,
is a marker of poor prognosis in patients with HNSCC
[7-9]. Mortality rate due to HNSCC is closely associated
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any medium, provided the original work is properly cited.with its potent capacity to metastasize distantly. There-
fore, an approach that decreases the metastatic ability of
HNSCC cells may facilitate the development of an effec-
tive strategy for its treatment and/or prevention.
Naturally occurring agents, particularly bioactive diet-
ary phytochemicals, may serve as appropriate candidates
for the prevention or therapy of HNSCC metastasis. If
these phytochemicals are safe and devoid of toxicities,
these can be considered for the prevention of cancer
cell invasion, migration or metastasis and thus can be
utilized as complementary and alternative medicine and/
or as adjuvant therapy for conventional cytotoxic thera-
pies. Grape seed proanthocyanidins (GSPs) are such
promising bioactive phytochemicals that have shown
anti-carcinogenic effects in some tumor models and
exhibit no apparent toxicity in vivo animal models
[10-12]. GSPs contain primarily proanthocyanidins
(89%), which constitute dimers, trimers, tetramers, and
oligomers of monomeric catechins and/or (-)-epicate-
chins, as described previously [11]. Although GSPs have
been shown to have anti-tumor effects [10], their che-
motherapeutic effects on the invasive potential of
HNSCC cells have not been explored.
In the current study, we assessed the chemotherapeu-
t i ce f f e c t so fG S P so nt h ei n v a s i o np o t e n t i a lo fh u m a n
head and neck cutaneous squamous cell carcinoma cells,
as the invasion of cancer cells is a major event in the
metastatic cascade. The invasion potential of cutaneous
SCC cells was also compared with the invasion potential
of human epidermoid carcinoma cells which were not
found on head and neck sub-sites. For this purpose, two
cutaneous SCC cells lines were selected: one is SCC13
which was generated from the squamous cell carcinoma
of the facial (head) skin. Second cell line is A431 which
is well known human epidermoid carcinoma cell line
and is not related with head and neck sub-sites. In this
study, we characterized the role of EGFR on the migra-
tion of head and neck cutaneous SCC cells and ascer-
tained whether GSPs have any suppressive effects on the
invasion of these cells and whether EGFR is involved in
this process. Epithelial-to-mesenchymal transition
(EMT), the process whereby epithelial cells transform
into mesenchymal cells, has been shown to be relevant
for cancer and cancer cell metastasis. During EMT, can-
cer cells lose expression of proteins that promote cell-
cell contact such as E-cadherin and acquire mesenchy-
mal markers such as vimentin, fibronectin and N-cad-
herin, which promote tumor progression, cell invasion
and metastasis [13,14]. The EMT has also been asso-
ciated with higher expression levels of EGFR and EGFR-
mediated signaling, therefore we have also checked
whether inhibition of EGFR expression by GSPs in head
and neck cutaneous SCC cells is associated with reversal
of EMT and that leads to inhibitory effect on cell
invasion of head and neck cutaneous SCC cells. Here,
we present evidence that GSPs inhibit the invasive
potential or migratory behavior of head and neck cuta-
neous squamous cell carcinoma cells through inhibition
or reversal of EMT and that GSPs do so through a pro-
c e s st h a ti n v o l v e st h er e d u c t i o ni nE G F Re x p r e s s i o n
level.
Methods
GSPs, source and composition
GSPs were received from Kikkoman Biochemifa Com-
pany, Japan (no financial conflict of interest). Quality
control of GSPs is maintained by the company on lot-
to-lot basis. GSPs contain approximately 89% proantho-
cyanidins, with dimers (6.6%), trimers (5.0%), tetramers
(2.9%) and oligomers (74.8%), as described earlier
[10-12]. Based on vendor’s information and analysis this
product is stable for at least two years when refrigerated
at 4°C. We have particularly selected this product as a
source of proanthocyanidins because it is commercially
available in purified form, and their composition is
known and maintained on lot-to-lot basis by the com-
mercial vendor. Some proanthocyanidins products are
also commercially available in the market and their
compositions are more or less comparable with the pro-
duct used in this study.
Cell lines and cell culture conditions
Human epidermoid carcinoma cells (A431) and human
head and neck cutaneous SCC cells SCC13 were
obtained from the American Type Culture Collection
(Manassas, VA) and normal human epidermal keratino-
cytes (NHEK) were obtained from Cell Culture Core
Facility of Skin Diseases Research Centre at the Univer-
sity of Alabama at Birmingham, AL. The cells were cul-
tured as monolayers in DMEM supplemented with 10%
heat inactivated fetal bovine serum, 100 μg/ml penicil-
lin-streptomycin (Invitrogen, Carlsbad, CA), and kept in
a humidified atmosphere of 5% CO2 at 37°C. The
NHEK were cultured in keratinocyte growth medium
supplemented with 5 ng/ml human recombinant epider-
mal growth factor and 0.05 mg/ml bovine pituitary
extract (Gibco/Invitrogen, Carlsbad, CA) and maintained
in an incubator under the identical conditions. Cells
were seeded at a density of 1 × 10
6 cells per petri dish
and allowed to attach for 24 h before treatment with
GSPs or other treatment agents. The sub-confluent cells
were treated with either various concentrations of GSPs
or other agents such as gefitinib or erlotinib. The GSPs,
erlotinib or gefitinib were dissolved in a small amount
of dimethylsulfoxide (DMSO), which was added to the
complete cell culture medium. The maximum concen-
tration of DMSO in media was 0.1% (v/v). Cells treated
with DMSO only served as a vehicle control. To
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(EGF)-mediated effects, GSPs were added in cell culture
medium at least 30 minutes before the treatment of the
cells with EGF.
Antibodies, chemicals and reagents
Boyden Chambers and polycarbonate membranes (8 μm
pore size) for cell invasion assays were obtained from
Neuroprobe, Inc. (Gaithersburg, MD). The antibodies
specific to N-cadherin, fibronectin, EGF, EGFR, ERK1/2
and b-actin were obtained from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA), while antibodies for vimentin and
E-cadherin were purchased from Cell Signaling Tech-
nology (Beverly, MA). The appropriate secondary anti-
bodies conjugated with horseradish peroxidase were
obtained from Invitrogen (Carlsband, CA).
Cell invasion assay
The invasion capacity of SCC cells was determined in
vitro using Boyden Chambers (Gaithersburg, MD). In
this assay, two chambers were separated with matrigel
coated Millipore membranes (6.5 mm diameter filters, 8
μM pore size), as detailed previously [15,16]. Briefly,
cancer cells (1.5 × 10
4 cells/100 μl serum-reduced med-
ium) were placed in the upper chamber of Boyden
chambers, test agents were added alone, or in combina-
tion, to the upper chamber (200 μl), and the lower
chamber contained the medium alone (150 μl). Cham-
bers were assembled and kept in an incubator for
desired time points. After incubation, cells from the
upper surface of Millipore membranes were removed
with gentle swabbing and the migratory cells on the
lower surface of membranes were fixed and stained with
crystal violet. The membranes were examined microsco-
pically and cellular invasion was determined by counting
the number of cells on membranes in at least 4-5 ran-
domly selected fields using an Olympus BX41 micro-
scope. Representative photomicrographs were obtained
using a Qcolor5 digital camera system fitted to an
Olympus BX41 microscope. Each cell invasion experi-
ment was repeated at least three times.
Scratch assay or wound healing assay
Scratch assay was performed to detect the cell migration
ability of SCC13 cells, as detailed previously [15]. Briefly,
SCC13 cells were grown to full confluency in six-well
plates and incubated overnight in starvation medium,
which contained only 0.5% FBS in DMEM cell culture
medium. Cell monolayers were wounded with a sterile
100 μl pipette tip, washed with starvation medium to
remove detached cells from the plates. Cells were left
either untreated or treated with selected concentrations
of GSPs in full medium and kept in a cell culture incu-
bator for 48 h. After 48 h, medium was replaced with
phosphate-buffered saline (PBS) buffer, the wound gap
was examined and cells were photographed using an
Olympus BX41 microscope fitted with digital camera.
Western blot analysis
Following treatment of cells for the indicated time peri-
ods with or without the treatment of GSPs or any other
agent, the cells were harvested, washed with cold PBS
and lysed with ice-cold lysis buffer supplemented with
protease inhibitors, as detailed previously [15,16]. Equal
amounts of proteins (50 μg) were resolved on 10% Tris-
Glycine gels and transferred onto a nitrocellulose mem-
brane. After blocking the non-specific binding sites, the
membrane was incubated with the primary antibody at
4°C overnight. The membrane was then incubated with
the appropriate peroxidase-conjugated secondary anti-
body and the protein bands were visualized using the
enhanced chemiluminescence reagents. The equal load-
ing of protein samples on the gel was verified after re-
probing the membrane with anti-b actin antibody.
Statistical analysis
For cell invasion assays, the control and GSPs, gefitinib
or erlotinib treatment groups or combined-treatment
groups separately were compared using one-way analysis
of variance (ANOVA) followed by post hoc Dunn’st e s t
using GraphPad Prism version 4.00 for Windows,
GraphPad Software, San Diego, California, USA, http://
www.graphpad.com. All quantitative data for cell migra-
tion are shown as the mean number of migrating cells ±
SD/microscopic field, n = 3. In each case P <0 . 0 5w a s
considered statistically significant.
Results
The invasive potential of head and neck cutaneous SCC13
cells was greater than A431 cells
First, we checked the invasive potential of head and neck
c u t a n e o u sS C C 1 3c e l l sa n dc o m p a r e di tw i t ht h a to f
human epidermoid carcinoma cell line A431, which are
not head and neck cancer cells, under identical experi-
mental conditions. As shown in Figure 1A and 1B, the
cell invasion ability of SCC13 cells was significantly
higher (P < 0.0001) than A431 cells. The number of inva-
sive SCC13 cells was 2000 ± 205 cells/microscopic field
while the invasion of A431 cells was 12 ± 2 cells/micro-
scopic field. These data indicate that cutaneous head and
n e c kS C Cc e l l sa r es t r o n g l ya g g r e s s i v ei nt e r m so ft h e i r
invasive potential than A431 cells which are not from the
head and neck sites. Under identical conditions, the inva-
sion potential of normal human epidermal keratinocytes
was not observed (data not shown).
As SCC13 cells were highly invasive in nature, we exam-
ined the invasion ability of SCC13 cells at the early time
points. As shown in Figure 1C, we could see the invasion
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bation. The migration of SCC13 cells was time dependent.
At 6 h time point, it was 70 ± 6; 12 h, 350 ± 20; and at 18
h, 850 ± 29 cells/microscopic field, as summarized in Fig-
ure 1D. After these preliminary observations, we selected
12 h time point for SCC13 cells for further studies on the
invasive potential of this cell line and to examine the inhi-
bitory effect of GSPs on its cell migration ability. Also, as
the migrating capacity of A431 cells was extremely lower
than SCC13 cells, we have selected only SCC13 cell line
for further mechanistic studies.
GSPs inhibit invasive potential of head and neck
cutaneous SCC cells: Boyden chamber assay
We determined whether treatment of SCC13 human
head and neck cutaneous SCC cells with GSPs inhibited
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Figure 1 Comparative cell invasion ability of human cutaneous squamous cell carcinoma cells. (A) Invasive ability of human epidermoid
carcinoma cells (A431) and head and neck cutaneous squamous cell carcinoma cells (SCC13) were compared. Equal numbers of cells were
subjected to cell invasion using standard Boyden chamber assay. Twenty-four h later, invasive cells were detected on the membrane after
staining with crystal violet. (B) The number of invasive cells were counted and the results expressed as the mean number of invasive cells ± SD/
microscopic field (n = 3). Significantly higher versus A431 cells, *P < 0.0001. (C) Time-dependent cell invasion potential of human head and neck
cutaneous SCC cells. (D) The invasive cells were counted and the results expressed as the mean number of invasive cells ± SD/microscopic field.
Significant higher invasion of cells versus 6 h time point, *P < 0.001;
¶P < 0.01.
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assays. First, screening experiments were performed to
determine the effects of lower (non-death inducing)
concentrations of GSPs (μg/ml). As shown in Figure 2A,
relative to untreated control cells, treatment of cells
with GSPs at concentrations of 0, 10, 20 and 40 μg/ml
reduced the invasive potential of SCC13 cells in a con-
centration-dependent manner. The density of the inva-
sive cells on the membrane after staining with crystal
violet is shown in Figure 2A, and the numbers of inva-
sive cells/microscopic field are summarized in Figure 2A
(right panel). The cell invasion was inhibited by18-85%
(P < 0.01-0.001) in SCC13 cells in a concentration-
dependent manner after treatment with GSPs for 12 h.
To verify that the inhibition of invasion of SCC13 cells
by GSPs was a direct effect on invasion ability, and that
was not due to a reduction in cell viability/cell death, a
trypan blue and/or MTT assays were performed [15]
using cells that were treated identically to those used in
the invasion assays. Treatment of SCC13 cells with var-
ious concentrations of GSPs (0, 10, 20 and 40 μg/ml)
for 12 h had no significant effect on cell viability or cell
death (data not shown).
GSPs inhibit the migration of head and neck cutaneous
SCC cells: Scratch or wound healing assay
As shown in Figure 2B, relative to untreated control cells,
treatment of cells with variousc o n c e n t r a t i o n so fG S P s
(10, 20 and 40 μg/ml) reduced the migration capacity of
SCC13 cells in a concentration-dependent manner after
the treatment of cells for 48 h. The major part of gap or
wounding space between cell layers after making a
wound was occupied by the migrating SCC13 cells which
were not treated with GSPs. However, the healing of the
wound or the empty space between the cell layers was
largely not occupied by the migrating cells treated with
GSPs and this effect was dose-dependent. The gap or
wounding space between the cells is highlighted by bro-
ken white lines (Figure 2B). These observations suggest
that GSPs inhibited the migration of SCC13 cells. To
further confirm that the inhibition of cancer cell migra-
tion by GSPs after 48 h was a direct effect on cell migra-
tion and not due to a reduction in cell viability, a trypan
blue assay was performed using cells that were treated
identically to those used in the migration assays. Treat-
ment of SCC13 cells with various concentrations of GSPs
(10, 20 and 40 μg/ml) for 48 h had no significant effect
on cell viability or cell death (data not shown).
The inhibitory effect of GSPs on invasive potential of
SCC13 cells is associated with the reduction of EGFR
expression
To determine whether the inhibitory effect of GSPs on
the invasion of the SCC13 cells is associated with
inhibition of EGFR expression, we determined the levels
of EGFR in lysates of cells from the various treatment
groups using western blot analysis. As shown in Figure
2C, treatment of SCC13 cells with GSPs for 12 h
reduced the levels of EGFR expression in a concentra-
tion-dependent manner as compared to the expression
in non-GSPs-treated controls. These results suggest that
GSPs-induced reduction in EGFR expression may be
associated with an inhibitory effect of the GSPs on the
cell invasion of these cells.
EGF, a ligand of EGFR, enhances the invasion of SCC13
cells, and GSPs inhibit EGF-induced cell invasion
EGF is a well known ligand of EGFR and has been
shown to stimulate the activity of EGFR; therefore, the
head and neck cutaneous SCC13 cells were treated with
EGF (10 ng/ml) for EGFR stimulation, and thereafter
determined the effect of EGF on the invasion of SCC13
cells. As shown in Figure 2D, treatment of SCC13 cells
with EGF for 12 h resulted in significantly enhanced cell
invasion (P < 0.01) compared to non-EGF-treated con-
trol cells. To determine whether GSPs inhibit EGF-
induced cell invasion in human head and neck cuta-
neous SCC13 cells, SCC13 cells were treated with EGF
(10 ng/ml) with and without the treatment of GSPs for
12 h. We found that the treatment of SCC13 cells with
GSPs (40 μg/ml) resulted in significant inhibition (P <
0.001) of EGF-induced invasion of SCC13 cells. A sum-
mary of the cell invasion data for the different treatment
groups is shown in Figure 2D (right panel).
Selective EGFR inhibitors, gefitinib and erlotinib, inhibit
the invasion of SCC13 cells
This experiment was performed to determine whether the
inhibitory effect of GSPs on the cell invasion of head and
neck cutaneous squamous cell carcinoma cells is mediated
through its inhibitory effect on EGFR expression. For this
purpose, SCC13 cells were subjected to the cell invasion
assay after treatment with various concentrations of gefiti-
nib (0, 0.1, 1.0 and 10.0 μM), a well known inhibitor of
EGFR, for 12 h. As shown in Figure 3A, treatment of the
cells with gefitinib resulted in a dose-dependent reduction
in the cell invasion capacity of SCC13 cells as compared
with non-gefitinib-treated controls (P < 0.05-0.001). These
data suggested that the inhibition of constitutive levels of
EGFR expression is associated with the inhibition of cell
invasion of head and neck cutaneous squamous cell carci-
noma cells. The resultant data on cell invasion/micro-
scopic field at different doses of gefitinib are summarized
in Figure 3B. Similar results were obtained when SCC13
cells were treated with another inhibitor of EGFR, erloti-
nib. Treatment of SCC13 cells with erlotinib for 12 h
inhibited the invasion capacity of these cells, as shown by
data summarized in Figure 3C.
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Figure 2 Effect of GSPs on cutaneous HNSCC cell invasion. (A) Treatment of cutaneous HNSCC cells (SCC13) with GSPs for 12 h inhibit invasion
of cells in a concentration-dependent manner compared to non-GSPs-treated control cells. The invasive cells were counted and the results
expressed as the mean number of invasive cells ± SD/microscopic field (right panel). Significant inhibition versus non-GSPs-treated control, *P <
0.001. (B) Wound healing assay was performed to assess the effect of GSPs on the migration of SCC13 cells. Incubation of SCC13 cells with GSPs for
48 h inhibits migration of cells in a concentration-dependent manner compared to non-GSPs-treated control cells. Broken white line indicates the
gap without the presence of cells. Representative pictures are shown from three separate experiments under identical conditions. (C) Dose-
dependent effect of GSPs on the EGFR expression of SCC13 cells. The levels of EGFR were determined in cell lysates using western blot analysis. (D)
GSPs inhibit EGF-induced invasion of SCC13 cells. Treatment of SCC13 cells with EGF results in enhancement of cell invasion, and treatment of GSPs
inhibit EGF-induced invasion of SCC13 cells. The data on cell invasion in each treatment group is summarized and the results expressed as the
mean number of invasive cells ± SD/microscopic field (right panel). Significant inhibition versus EGF alone-treated group, *P < 0.001.
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Figure 3 Effect of gefitinib, an inhibitor of EGFR, on SCC13 cell invasion. (A) Treatment of human head and neck cutaneous squamous cell
carcinoma cells with gefitinib, a small molecule inhibitor of EGFR, for 12 h inhibits invasion of cells in a concentration-dependent manner. (B)
The invasive cells were counted and the results expressed as the mean number of invasive cells ± SD per microscopic field. (C) Treatment of
SCC13 cells with erlotinib, an inhibitor of EGFR, inhibited cell invasion. Significant reduction of cell invasion versus untreated control cells,
¶P <
0.05, *P < 0.001. (D) Transfection of cells with EGFR-siRNA significantly decreases cell invasion. SCC13 cells were transfected with EGFR-siRNA to
knockdown EGFR expression (left panel). Significant reduction of cell invasion versus control siRNA-treated cells, *P < 0.001 (right panel). (E)
Western blot analysis revealed that transfection of SCC13 cells with EGFR-siRNA resulted in marked reduction in the levels of EGFR in cells.
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SCC13 cells
We further verified the role of EGFR in cell invasion
through siRNA knock-down of EGFR in the SCC13 cells
using siRNA Transfection Reagent Kit (Santa Cruz Bio-
technology, Inc., Santa Cruz, CA), and examined
whether it would lead to the inhibition of the cell inva-
sion in these cells. The data from cell invasion assay
revealed that transfection of SCC13 cells with EGFR
siRNA resulted in significant reduction of cell invasion
(84%, P <0 . 0 0 1 )a f t e r1 2ha sc o m p a r e dt ot h ei n v a s i o n
of control siRNA-transfected SCC13 cells (Figure 3D,
left and right panels). We also confirmed using western
blot analysis that EGFR siRNA transfection of SCC13
cells resulted in marked reduction in the levels of EGFR
protein (> 80%) in these cells (Figure 3E).
GSPs inhibit the activation of ERK1/2 in SCC13 cells, and
MEK inhibitor reduces the invasion potential of SCC13
cells
Mitogen-activated protein kinases (MAPK) are down-
stream target of EGFR signaling, and have been impli-
cated in cancer cell metastasis [17]. Therefore, we exam-
ined the effect of GSPs on activation of extracellular-
signal regulated kinase (ERK1/2) in head and neck cuta-
neous SCC cells. Western blot analysis revealed that
treatment of SCC13 cells with GSPs for 12 h inhibited
the phosphorylation of ERK1/2 in a dose-dependent
manner, as shown in Figure 4A. We further verified the
role of activated ERK1/2 on SCC13 cell invasion by
using the inhibitor of MEK (UO126). Cell invasion assay
revealed that treatment of SCC13 cells with UO126 for
12 h significantly inhibited (P < 0.001) the invasion of
cells (Figure 4B). A summary of data obtained from
three independent experiments related with cell invasion
is shown in Figure 4C. Additionally, western blot analy-
sis revealed that the level of phosphorylated ERK1/2 was
also decreased after the treatment of cells with MEK
inhibitor UO126, as shown in Figure 4D.
GSPs reverse epithelial-to-mesenchymal transition in
SCC13 cells
Upregulation of EGFR and activation of downstream
targets like ERK1/2 play a critical role in EMT [13,17],
which in turn has been involved in cancer cell invasion
and metastasis. To check if GSPs affect EMT in HNSCC
cells, we examined if there is any change in SCC13 cells
morphology after their treatment with low-dose GSPs
under an inverted phase-contrast microscope (Figure
5A). For this purpose cells were treated with and with-
out GSPs (20 μg/ml) for 12 h. As shown in Figure 5A,
we found that culturing cells with GSPs for 12 h
resulted in morphological changes of these cells from a
spindle shaped or fibroblast-like shape to an epithelial-
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Figure 4 GSPs inhibit SCC13 cell invasion by inhibiting
activation of ERK1/2. (A) GSPs inhibit the activation of ERK1/2 in
SCC13 cells dose-dependently. (B) Treatment of SCC13 cells with
MEK inhibitor (UO126, 80 μM) inhibits the invasion of cells
compared to non-MEK inhibitor-treated control cells. (C) The data
on cell invasion capacity are summarized and expressed as the
mean number of invasive cells ± SD/microscopic field, n = 3.
Significant difference versus control *P < 0.001. (D) The treatment of
cells with MEK inhibitor also inhibits the activation of ERK1/2 in cells
as determined by western blot analysis. Representative blot is
shown from three separate experiments.
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Page 8 of 12like shape. This change on cell morphology suggested
that there was a transition of mesenchymal state to
epithelial state under the influence of GSPs.
Next, we determined whether GSPs affect or reverse
the biomarkers of EMT in head and neck cutaneous
SCC cells and that is responsible for their inhibitory
effect on the invasiveness of SCC13 cells. For this pur-
pose, SCC13 cells were treated with GSPs for 12 h, and
cell lysates were prepared for the western blot analyses
of various epithelial and mesenchymal biomarkers. Wes-
tern blot analyses revealed that GSPs increased the
levels of E-cadherin, an epithelial biomarker, in SCC13
cells in a dose-dependent manner compared to
untreated controls (Figure 5B). In contrast, the levels of
mesenchymal biomarkers, such as N-cadherin, vimentin
and fibronectin, were reduced in SCC13 cells after treat-
ment with GSPs in a dose-dependent manner, as shown
in Figure 5C. Similarly, treatment of SCC13 cells with
erlotinib, an inhibitor of EGFR, for 12 h resulted in
reduced expression of mesenchymal biomarkers, such as
N-cadherin, vimentin and fibronectin, as evident by the
western blot analysis (Figure 5D).
Discussion
The metastasis of cancer cells is considered as a major
cause of human death and mortality in any type of can-
cer. Treatment is difficult if cancer cells spread beyond
the primary site of the tumor. Therefore, innovative
strategies are required to be developed for the preven-
tion of the invasive potential of cancer cells. In this
study we found that head and neck cutaneous SCC cells
are much more aggressive in terms of their invasion
potential than other human skin cancer cells, such as
A431 cells, which are well known human epidermoid
carcinoma cells. Milliri et al [18] reported that the inva-
sion potential of SCC-derived cells is dependent upon
EGF stimulation, and this response to EGF does not
occur in benign epidermal cells. Also, this response does
not occur in A431 cells because these cells have sus-
tained expression of the c-Jun deletion mutant, TAM67,
which inhibits EGF-induced cytoskeletal rearrangements
necessary for lamellipodia formation and cell rounding
and ultimately cell motility and invasion.
The significant findings in the present study are that
the treatment of head and neck cutaneous SCC cells
with GSPs inhibits invasive potential of cells in a dose-
dependent manner, and that is associated with the
down-regulation of EGFR expression in cells. The head
and neck cutaneous SCC13 cells over-express EGFR,
and the inhibition of EGFR by GSPs contributes to the
inhibition of cell invasion of these cells. This concept is
supported by the evidence that treatment of the SCC13
cells with gefitinib or erlotinib, which are potent inhibi-
tor of EGFR, resulted in a reduction of cell invasion.
A
Control GSPs
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0    10     20      40
GSPs (g/ml) B
ȕ-actin
N-cadherin
Vimentin
0    10     20     40
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C
Vimentin
Fibronectin
ȕ -actin
Vimentin
N-cadherin
D
E-cadherin
Fibronectin
ȕ-actin
Erlotinib (M)
0         2         5
( )
Figure 5 Treatment of SCC13 cells with GSPs reverses
epithelial-to-mesenchymal transition. (A) Treatment of SCC13
cells with GSPs for 12 h resulted in loss of mesenchymal structure
or morphology of cells. Cells lost their spindle shape morphology.
Inset pictures showed magnified cell structure. (B) Treatment of
cells with GSPs enhances the levels of E-cadherin, an epithelial
biomarker, in the cells dose-dependently. (C) Treatment of cells with
GSPs decreases the levels of mesenchymal biomarkers in SCC13
Sun et al. BMC Complementary and Alternative Medicine 2011, 11:134
http://www.biomedcentral.com/1472-6882/11/134
Page 9 of 12Similar effects were also noted when the SCC13 cells
were transfected with EGFR-siRNA. Treatment of cells
with EGF stimulates EGFR, and we observed that treat-
ment of SCC13 cells with EGF enhances cell invasion
ability, and that this EGF-induced cell invasion was
blocked by the treatment of cells with GSPs. These
observations support the evidence that inhibition of
head and neck cutaneous squamous cell carcinoma cell
invasion by GSPs is mediated through their inhibitory
effects on EGFR expression. It has been reported that
inhibitors of EGFR can prevent the growth and progres-
sion of HNSCC; however, long term use may also
induce some form of toxicity [19,20]. This possibility is
not expected with the use of GSPs as these are dietary
components and toxicity has not been observed in ani-
mal models [11,12].
Proteins of MAPK family are a downstream target of
EGFR, and have been shown to play a crucial role in
cells, such as N-cadherin, vimentin and fibronectin, in a dose-
dependent manner. (D) Treatment of SCC13 cells with erlotinib, an
inhibitor of EGFR, for 12 h decreases the levels of mesenchymal
biomarkers, such as N-cadherin, vimentin and fibronectin.
Gefitinib
MEK
GSPs
UO126
EMT
ERK
Cell invasion
GSPs
Low Mortality Rate
Figure 6 Summary of GSPs action on the prevention of SCC13 cell invasion. GSPs inhibit the expression levels of EGFR in human
cutaneous head and neck squamous cell carcinoma cells, which plays a critical role in inactivation of ERK1/2 and reversal of epithelial-to-
mesenchymal transition and that leads to inhibition of cell invasion potential.
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Page 10 of 12cancer cell invasion. Our results show that inhibition of
invasion of SCC13 cells by GSPs is associated with the
inhibition of ERK1/2 phosphorylation. The inhibition of
MEK with UO126, a MEK inhibitor, blocked the inva-
sion capacity of SCC13 cells which is similar to the
action of GSPs. These observations suggest a possible
involvement of ERK1/2/MAPK pathway in inhibition of
the invasion of cutaneous HNSCC cells. Activation of
the proteins of MAPK family leads to the activation NF-
B which play an important role in multiple biological
processes, including inflammation, cell proliferation and
angiogenesis [21-23]. Importantly, NF-B has been iden-
tified as an important regulator of EMT in several can-
cer cell types [21-24]. EMT has been implicated in
invasion and metastasis of epithelial tumors. EMT can
render tumor cells migratory and invasive through the
involvement of all stages: invasion, intravasation and
extravasation [13,14]. During the process of EMT, cells
c a nc h a n g ef r o ma ne p i t h e l i a l to a mesenchymal state.
They lose their characteristic epithelial traits and instead
gain properties of mesenchymal cells. This process is
primarily coordinated by the disappearance or loss of
epithelial biomarkers such as E-cadherin with the con-
comitant appearance or gain of mesenchymal markers
such as vimentin, fibronectin and N-cadherin, etc. In
the present study, GSPs treatment of SCC13 cells
showed the suppression of mesenchymal biomarkers,
such as vimentin, fibronectin and N-cadherin while
restored the levels of epithelial biomarker such as, E-
cadherin, in human cutaneous head and neck SCC cells
which suggest that GSPs have the ability to reverse the
EMT process in HNSCC cells. These information sug-
gest that reversal of EMT in SCC13 cells by GSPs may
also be one of the possible mechanisms through which
GSPs reduce the invasiveness of cutaneous head and
neck squamous cell carcinoma cells and that lead to
inhibition of invasion of SCC13 cells in our system. A
recent study showed that GSPs inhibit invasion of mela-
noma cancer cells and this inhibitory effect of GSPs on
melanoma cell invasion was associated with their inhibi-
tory effect on COX-2 overexpression and successive
down-regulation of NF-B and reversal of EMT process
[25]. Similar to GSPs, other phytochemicals, such as
berberine, have also been shown to inhibit the invasion
potential of cancer cells. Berberine inhibits the invasion
of melanoma cancer cells through its inhibitory effect
on endogenous COX-2 overexpression and successive
down-regulation of prostaglandin E2 and prostaglandin
E2 receptors [16].
Conclusion
The results from this study have identified for the first
time that GSPs inhibit the invasiveness of human cuta-
neous HNSCC cells and that involves: (i) the inhibitory
effect of GSPs on endogenous EGFR overexpression, (ii)
the inhibitory effect of GSPs on the activation of the
ERK1/2 proteins of MAPK family, and (iii) the reversal
of EMT process, as summarized in Figure 6. More
detailed studies are needed to develop GSPs as a phar-
macologically safe agent either alone or in combination
with other anti-metastatic drugs for the treatment of
cutaneous head and neck SCCs in humans.
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